Navigation Links
Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
Date:4/18/2008

was comparable across all infusion durations (10-, 15- and 30-minute infusions), with headache (5%, 7%, 8%) and dizziness (5%, 6%, 8%) being the most commonly reported. Plasma concentrations were proportional to the actual daily dose given and similar across all infusion duration groups. Intravenous lacosamide was also locally well-tolerated with no serious infusion site reactions. In this study, intravenous lacosamide was administered directly via injection, with no diluent required.

These results support data from an earlier multi-center, double-blind, randomized, inpatient trial that evaluated intravenous lacosamide (200-600 mg/day) as replacement for oral lacosamide in patients with partial onset seizures. In that double-blind trial, intravenous lacosamide showed a similar profile to oral lacosamide when administered as 30- or 60-minute twice daily infusions. The data presented at AAN demonstrated that intravenous lacosamide was also generally well-tolerated at shorter infusion durations.

Intravenous lacosamide was developed as an alternative for patients who temporarily cannot receive oral therapy. Doses of intravenous lacosamide are equivalent to the oral form of the drug and do not require conversion.

About lacosamide: Lacosamide has a dual mode of action and is the first agent of its kind to be clinically studied for the treatment of epilepsy. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target-collapsin-response mediator protein-2 (CRMP-2). Lacosamide is also being investigated for its potential effect in reducing diabetic neuropathic pain.

Lacosamide-oral tablet, oral syrup and intravenous formulation-has been filed with the U.S. FDA and the EMEA for use as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy and is currently under review.

Applications for marketing authorization for lacosamide in epilepsy are supported by da
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
2. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
3. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
4. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
5. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
6. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
7. PG500 Series Presented at the AACR Annual Meeting in San Diego
8. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
11. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... ThermoGenesis Corp. (NASDAQ: KOOL ), a ... and administration of cell therapies, today said that it ... Platform (AXP) used for the processing of cord blood. ... in the country later this year. "We ...
... Mass., May 22, 2012  Halo Therapeutics, LLC, a ... fibrotic diseases, announced today that it has received ... serving the muscular dystrophy patient community. Halo will ... study of HT-100, its lead drug candidate for ...
Cached Medicine Technology:ThermoGenesis Announces Axp Approval In Thailand 2ThermoGenesis Announces Axp Approval In Thailand 3Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 2Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 3
(Date:7/10/2014)... 2014 (HealthDay News) -- Teens who are sensitive to ... to develop emotional symptoms such as anxiety and depression, ... these that may exacerbate issues teens experience after concussion ... in making decisions about when to return to play ... athletes," study authors Lisa Koehl and Dong Han, of ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... use of calorie information on menus, if it,s available, to ... U.S. study. Women in particular review the menu labeling, ... with the U.S. Centers for Disease Control and Prevention. ... to help choose their meal, compared with just under half ...
(Date:7/10/2014)... with a microchip-based device developed at the Massachusetts General ... MGH Cancer Center can be cultured to establish cell ... the July 11 issue of Science , an ... reflect a tumor,s genetic mutation over time and changing ... culture cells from the blood that represent those present ...
(Date:7/10/2014)... Human Services (HHS) has announced a three-year grant to ... totaling $4.7 million to support a new national model ... , Titled "Evidence-Conformant Oncology Care," the project will ... care for adult cancer patients with late-stage disease, significant ... , "We believe that the best cancer ...
(Date:7/10/2014)... Katerina Alba,s research at the University of Huddersfield could ... most popular emulsion-based food products such as butter, ... starting to gain an international profile for her work. ... food science at the University and now she has ... her supervisor, Dr Vassilis Kontogiorgos, she is investigating the ...
Breaking Medicine News(10 mins):Health News:Some Teens May Face Emotional Problems After Concussion 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:World interest in research work on the benefits of the Okra plant 2
... ... innovators in 15 countries participate in SharpBrains Summit without taking a single flight ... ... company focused on brain fitness, today announced the inaugural SharpBrains Summit, the first ...
... WASHINGTON , Jan. 12 The American Lung Association ... report, which grades the strength of federal and state laws ... the heart of America,s chronic disease crisis. , The report ... has significant room for progress. Most state governments , however, ...
... ... in Developing Countries , ... Trevose, PA (PRWEB) January 12, 2010 -- International SOS, ... customer care, has signed a memorandum of understanding with MediSend International to support ...
... ... Services, Inc. have joined forces to provide quality employee benefit programs throughout Tennessee and ... ... of tax-advantaged medical and other benefit account management services, announces the acquisition of Tennessee ...
... ... lead international business development. Foreman has a proven track record of success in video ... ... leading global provider of Video Streaming solutions, announces that Dan Foreman will head their ...
... , , LOS ... International Airport (LAX), in partnership with FLU*Ease, Inc., is ... airline terminals as a public safety measure against the flu, ... FLU*Ease stations, complete with privacy screens, are set up beyond ...
Cached Medicine News:Health News:First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains 2Health News:First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains 3Health News:First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains 4Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 2Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 3Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 4Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 5Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 6Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 7Health News:American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease 8Health News:International SOS and MediSend to Partner on Humanitarian Healthcare 2Health News:International SOS and MediSend to Partner on Humanitarian Healthcare 3Health News:TASC Partners with Unity Benefit Services, Inc. 2Health News:ActiveGroup expands into Europe by hiring Market Research Leader 2Health News:Flu Shots Now Offered in Los Angeles International Airport Terminals 2
... endoscope is the first Video ... instrument incorporates a 2.0mm instrument ... insertion tube. The slim size ... easy introduction even through areas ...
... Used for temporary internal drainage from ... Supplied sterile in peel-open packages. Intended ... is advised; C-Flex® and Sof-Flex® stents ... six (6) months; silicone stents must ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
... Double Pigtail Ureteral Stents have an ... maximizes migration. They also feature unique ... cost savings. Each Classic Double PigTail ... Double PigTail Ureteral Stent with attached ...
Medicine Products: